---
document_datetime: 2025-11-21 15:11:07
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/invanz-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: invanz-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 18.9397781
conversion_datetime: 2025-12-27 15:47:04.6198
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Invanz

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific informationafterauthorisation(archive).

| Applicationnumber   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|---------------------|----------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Article 61(3) /     | Notification acc.Article61(3)-Accepted | 21/11/2025                          |                                          | PL                              |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000312910                      | Update of the package leaflet with revised contactdetails of local representatives.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |             |                                                                                                                                                                                                                                                                                                                           |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000245061 | Thiswas anapplicationfor agroupof variations. B.I.a.1 Change in the manufacturer of a startingmaterial/reagent/intermediateused inthemanufacturingprocessoftheactive substanceorchangeinthemanufacturer (includingwhererelevantquality control testing sites)ofthe active substance,where noPh.Eur.Certificate of Suitability is part of the approved dossier - B.I.a.1.f Changes to qualitycontrol testingarrangementsforthe active substance-replacement or addition of a site where batch control/testing takes place - Accepted B.I.a.1 Change in the manufacturer of a startingmaterial/reagent/intermediateused inthemanufacturingprocessoftheactive substanceorchangeinthemanufacturer (includingwhererelevantquality control testingsites)oftheactive substance,where noPh.Eur.Certificate ofSuitability ispart of the approved dossier-B.I.a.1.z Other variation-Accepted B.I.a.1Changeinthemanufacturerofa | 24/07/2025 | SmPC and PL | SmPC section 3 is updated to reflect an updated description of the finished product,section5.1 is updatedtoreplace theMICbreakpointstablewith theagreedreferencetotheEMAwebsite.Analogous changes aremade tothePackageLeaflet.Additional minortypographical changesinlinewith theQRD template aremade throughout theSmPC. |

<div style=\"page-break-after: always\"></div>

| in themanufacturingprocessof theactive substance or changein themanufacturer (including where relevant quality control testing sites)of the active substance,where no Ph. Eur. Certificate of Suitability is part of the approved dossier-B.I.a.1.gIntroduction ofanewmanufactureroftheactive substance that is not supported by an ASMF andrequiressignificant update tothe relevant active substance section of the dossier-Accepted  B.II.d.1Changeinthespecification parameters and/or limits of the finished product - B.II.d.1.z Change in the microbiological purity specification parameters of the finished product to comply with Ph.Eur.A change to the finished products specifications in order to comply with Ph.Eur.could also possiblybe acceptableasaTypeIAnotification in certain circumstances, takinginto account thegeneralacceptancethatthenewlimits are acceptableforthe specificdosageforms. It is up to the Applicant to provide all necessarydataforthejustification of the classification.- Accepted  B.II.d.2 Change in test procedurefor the finishedproduct-B.II.d.2.aMinor changes to an approved testprocedure-Accepted   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>